All In Biotech

Drug Trial Radar · NCT07765446

Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel

A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Aug 21, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Sironax USA, Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).

Conditions

  • Chemotherapy-induced Peripheral Neuropathy

Interventions

  • SIR2501Drug

    Experimental: 30 mg SIR2501 administered at 30 mg dose level. Experimental: 45 mg SIR2501 administered at 45 mg dose level. Experimental: 60 mg SIR2501 administered at 60 mg dose level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary OutcomeTime frame: From first dose through 1 month after last dose

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hollywood, Florida · Recruiting

  • Site not named

    Baltimore, Maryland · Recruiting

  • Site not named

    Boston, Massachusetts · Not yet recruiting

  • Site not named

    East Brunswick, New Jersey · Recruiting

  • Site not named

    Winston-Salem, North Carolina · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.